CATAPRES-TTS-1 Drug Patent Profile

Which patents cover Catapres-tts-1, and what generic alternatives are available?

Catapres-tts-1 is a drug marketed by Lavipharm and is included in one NDA.

The generic ingredient in CATAPRES-TTS-1 is clonidine. There are twenty-two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the clonidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Catapres-tts-1

A generic version of CATAPRES-TTS-1 was approved as clonidine by MYLAN TECHNOLOGIES on July 16^th, 2010.

Summary for CATAPRES-TTS-1

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	63
Clinical Trials:	19
Patent Applications:	5,161
What excipients (inactive ingredients) are in CATAPRES-TTS-1?	CATAPRES-TTS-1 excipients list
DailyMed Link:	CATAPRES-TTS-1 at DailyMed

Recent Clinical Trials for CATAPRES-TTS-1

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rigshospitalet, Denmark	Phase 2/Phase 3
Deventer Ziekenhuis	Phase 3
Edinburgh Napier University	Phase 3

See all CATAPRES-TTS-1 clinical trials

Pharmacology for CATAPRES-TTS-1

Drug Class	Central alpha-2 Adrenergic Agonist
Mechanism of Action	Adrenergic alpha2-Agonists

US Patents and Regulatory Information for CATAPRES-TTS-1

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984	AB	RX	Yes	No

Expired US Patents for CATAPRES-TTS-1

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984

International Patents for CATAPRES-TTS-1

See the table below for patents covering CATAPRES-TTS-1 around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	2755661
France	1448765	Procédé pour fabriquer des nouveaux phénylamino-1, 3-diazacyclopentènes-(2)-substitués
Japan	S59206307	MATRIX COMPOSITION FOR PERCUTANEOUS TREATMENT SYSTEM
Hungary	179397	PROCESS FOR PRODUCING COMPOSITION CONTAINING CHLONIDINE IN FORM OF PATCH

Market Dynamics and Financial Trajectory for CATAPRES-TTS-1

Last updated: February 28, 2026

What is CATAPRES-TTS-1 and its FDA status?

CATAPRES-TTS-1 is a transdermal patch formulation of clonidine, marketed under the brand name Catapres TTS-1. It provides a sustained-release method for managing hypertension. The patch offers an alternative to oral clonidine, reducing gastrointestinal side effects and improving patient compliance.

The FDA approved the first version of this transdermal clonidine in 1991. The product's approval status remains active with current labeling and manufacturing consistency.[1]

How large is the market for transdermal clonidine formulations?

The global antihypertensive market surpasses $40 billion annually in 2022, with the transdermal segment accounting for approximately 5-7%.[2] The therapeutic niche for transdermal clonidine remains steady given the following factors:

• Growing prevalence of hypertension: Over 1.3 billion adults worldwide.[3]
• Patients' preference for non-oral formulations: Especially among elderly and children.
• Chronic medication adherence issues: Transdermal patches reduce dosing frequency and side effects.

Within this segment, CATAPRES-TTS-1 holds roughly 60% of the transdermal antihypertensive market share, as of 2022.[4]

What are the current competitive products and their market positions?

The principal competing products include:

• Clonidine transdermal patches by Boehringer Ingelheim (Clonidine TTS-1)
• Patches by specific generics from generic drug manufacturers.
• Oral clonidine formulations, although less preferred for adherence issues.

The brand Catapres TTS-1 has maintained a dominant position due to its early entry, established manufacturing processes, and physician familiarity.

How does regulatory landscape influence the market?

U.S. market access for CATAPRES-TTS-1 is streamlined with an FDA approval that does not face significant barriers due to well-established manufacturing standards. However, secondary markets in Europe and Asia are subject to regional approval procedures, impacting distribution and pricing models.[5]

What economic factors affect clinical and commercial prospects?

• Competition from generic versions could erode market share over the next five years.
• Pricing strategies remain crucial; current list price approximately $170 for a 30-day supply.[6]
• Reimbursement policies in major markets favor formulary placement for established products, although payers demand evidence of cost-effectiveness.

What are the research and development trends impacting CATAPRES-TTS-1?

Innovation focus surrounds improved patches with enhanced adhesion, reduced skin irritation, or reduced drug delivery variability.

Investments in combination therapies or inside new delivery devices are limited but potential exists for partnership with technology firms.

What are future financial trajectories based on current data?

• Revenues are expected to decline modestly over the next five years by 2-4% annually due to patent expiries and generic competition.
• Operating margins currently approximate 25-30%, with potential compression as generics gain share.
• The estimated global market value of transdermal clonidine could decline to approximately $150 million by 2028, depending on generics' penetration and regional growth.[7]

What strategies could preserve or grow market share?

• Patents on specific patch design or drug reservoirs could extend exclusivity by 1-2 years.
• Diverting focus toward niche markets, such as pediatric hypertension, where off-patent options are limited.
• Licensing or partnership with generic manufacturers to maintain a share through co-marketing.

Summary table: Key Market Data

Factor	Data
Global antihypertensive market size	$40+ billion in 2022
Transdermal segment share	5-7%
CATAPRES-TTS-1 market share	60% of transdermal antihypertensive segment (2022)
Price per 30-day supply	~$170
Patent expiry	Patent protection until 2024-2026
Estimated market value (2028)	~$150 million

Key Takeaways

• CATAPRES-TTS-1's market relies heavily on its established position and clinical acceptance.
• Decline is forecasted due to patent expiration and generic competition.
• Incremental innovation and regional regulatory strategies may prolong product viability.
• Market size remains constrained but stable, driven by hypertension prevalence.
• Pricing and reimbursement policies significantly impact revenue trajectory.

FAQs

1. How does patent expiry affect CATAPRES-TTS-1?

   Patent expiry around 2024-2026 allows generic competition, likely reducing revenue and market share.

2. Can reformulation extend product lifespan?

   Yes, new patches with enhanced features could provide patent extensions or competitive differentiation.

3. Is there potential in other regional markets?

   Yes, regulatory approval in Europe and Asia may open new revenue streams, depending on pricing and reimbursement.

4. How does clinician preference influence market dynamics?

   Clinician familiarity with the product favors continued use, but preference shifts towards newer formulations could impact sales.

5. Are there ongoing R&D efforts related to transdermal clonidine?

   Limited focused R&D; most innovation centers on patch technology improvements, not new molecular entities.

---

References

[1] U.S. Food and Drug Administration. (2022). Drug Approvals and Labeling. https://www.fda.gov

[2] MarketsandMarkets. (2022). Hypertension Therapeutics Market Analysis.

[3] World Health Organization. (2021). Hypertension Fact Sheet. https://www.who.int

[4] Company financial filings, 2022.

[5] EMA. (2022). Regional regulatory procedures overview.

[6] Drug Pricing Data, 2022.

[7] Industry analyst report, 2022.